Abstract
Cancer hallmarks help in understanding the diversity of various neoplasms. Epithelial cancers play an immense role in the tumor biology through Epithelial-Mesenchymal Transition (EMT) process. Receptor tyrosine kinase, as well as phosphatidyl ionositol-3 kinase pathways, play an important role in the regulation of cell proliferation, survival, and differentiation during EMT. Till date, numerous studies have shown modulation in the expression profile of potential targets like CD44, EGFR, and Rac in epithelial cancers. CD44 interacts with EGFR and recruits other molecules which further activate the Rac pathway intermediates. This review mainly focused on modulation of genes like CD44, EGFR, and Rac pathway intermediates which play a crucial role in the tumor progression, metastasis, proliferation, and invasion characteristics in epithelial cancers with EMT properties. Hence, targeting Rac pathway might be a more strategically relevant approach in treating epithelial cancers.
Keywords: CD44, EGFR, invasion, metastasis, proliferation, rac.
[3]
Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 2011; 32(4): 605-44.
[4]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66(2): 115-32.
[5]
Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med 2017; 14(1): 9-32.
[6]
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127(12): 2893-917.
[7]
Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol 2014; 5(3): 283-98.
[8]
Hong I, Hong SW, Chang YG, et al. Expression of the cancer stem cell markers CD44 and CD133 in colorectal cancer: an immunohistochemical staining analysis. Ann Coloproctol 2015; 31(3): 84-91.
[9]
Garza-Treviño EN, Said-Fernández SL, Martínez-Rodríguez HG. Understanding the colon cancer stem cells and perspectives on treatment. Cancer Cell Int 2015; 15(1): 2.
[10]
Yun E-J. Lo U-G, Hsieh J-T. The evolving landscape of prostate cancer stem cell: Therapeutic implications and future challenges. Asian J Urol 2016; 3(4): 203-10.
[11]
Jain S, Saxena S, Kumar A. Epidemiology of prostate cancer in India. Meta Gene 2014; 2: 596-605.
[13]
Hidalgo M, Cascinu S, Kleeff J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology 2015; 15(1): 8-18.
[14]
Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol 2016; 22(44): 9694-705.
[15]
Kaboodkhani R, Karimi E, Khorsandi Ashtiani MT, et al. Evaluation of the Correlation between CD44, Tumor Prognosis and the 5-Year Survival Rate in Patients with Oral Tongue SCC. Iran J Otorhinolaryngol 2016; 28(89): 407-11.
[16]
Liang H, Fan J-H, Qiao Y-L. Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. Cancer Biol Med 2017; 14(1): 33-41.
[17]
Xu Z, Zou L, Ma G, et al. Integrin β1 is a critical effector in promoting metastasis and chemo-resistance of esophageal squamous cell carcinoma. Am J Cancer Res 2017; 7(3): 531-42.
[18]
Jiang D, Li X, Wang H, et al. The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma. BMC Cancer 2015; 15(1): 377.
[19]
Farmer R. Prostate cancer: epidemiology and risk factors. Trends Urol Men’s Health 2008; 13(3): 32-4.
[20]
La Vecchia C. Ovarian cancer: epidemiology and risk factors. Eur J Cancer Prev 2017; 26(1): 55-62.
[21]
Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 2005; 24(50): 7443-54.
[22]
Zhang P, Sun Y, Ma L. ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle 2015; 14(4): 481-7.
[23]
Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010; 15(2): 117-34.
[24]
Jiang Z-S, Sun YZ, Wang SM, Ruan JS. Epithelial-mesenchymal transition: potential regulator of ABC transporters in tumor progression. J Cancer 2017; 8(12): 2319-27.
[25]
Chen A, Beetham H, Black MA, et al. E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. BMC Cancer 2014; 14(1): 552.
[26]
Lindsey S, Langhans SA. Crosstalk of oncogenic signaling pathways during epithelial–mesenchymal transition. Front Oncol 2014; 4: 358.
[28]
Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141(7): 1117-34.
[29]
Boyer B, Vallés AM, Edme N. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 2000; 60(8): 1091-9.
[30]
Wang W, Liu Y, Liao K. Tyrosine phosphorylation of cortactin by the FAK-Src complex at focal adhesions regulates cell motility. BMC Cell Biol 2011; 12(1): 49.
[31]
Schwock J, Dhani N, Hedley DW. Targeting focal adhesion kinase signaling in tumor growth and metastasis. Expert Opin Ther Targets 2010; 14(1): 77-94.
[32]
Zenonos K, Kyprianou K. RAS signaling pathways, mutations and their role in colorectal cancer. World J Gastrointest Oncol 2013; 5(5): 97-101.
[33]
Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16(1): 103-19.
[34]
Nandan MO, Yang VW. An update on the biology of RAS/RAF mutations in colorectal cancer. Curr Colorectal Cancer Rep 2011; 7(2): 113-20.
[35]
Tsou W-I, Nguyen KQ, Calarese DA, et al. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation. J Biol Chem 2014; 289(37): 25750-63.
[36]
Rankin EB, Giaccia AJ. The Receptor Tyrosine Kinase AXL in Cancer Progression. Cancers (Basel) 2016; 8(11): 103.
[37]
Gustafsson A, Martuszewska D, Johansson M, et al. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res 2009; 15(14): 4742-9.
[38]
Koorstra J-BM, Karikari CA, Feldmann G, et al. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 2009; 8(7): 618-26.
[39]
Hector A, Montgomery EA, Karikari C, et al. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther 2010; 10(10): 1009-18.
[40]
Lee C-H, Yen CY, Liu SY, et al. Axl is a prognostic marker in oral squamous cell carcinoma. Ann Surg Oncol 2012; 19(3)(Suppl. 3): S500-8.
[41]
Dunne PD, McArt DG, Blayney JK, et al. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin Cancer Res 2014; 20(1): 164-75.
[42]
Brand TM, Iida M, Stein AP, et al. AXL is a logical molecular target in head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21(11): 2601-12.
[43]
Ou WB, Corson JM, Flynn DL, et al. AXL regulates mesothelioma proliferation and invasiveness. Oncogene 2011; 30(14): 1643-52.
[44]
Ammoun S, Provenzano L, Zhou L, et al. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival. Oncogene 2014; 33(3): 336-46.
[45]
Castellano E, Downward J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2011; 2(3): 261-74.
[46]
Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 2012; 4(9): a011189.
[47]
McCubrey JA, Steelman LS, Chappell WH, et al. Ras/Raf/MEK/ ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012; 3(10): 1068-111.
[48]
Xue G, Hemmings BA. PKB/Akt-dependent regulation of cell motility. J Natl Cancer Inst 2013; 105(6): 393-404.
[49]
Louderbough JM, Schroeder JA. Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res 2011; 9(12): 1573-86.
[50]
Li G, Gao Y, Cui Y, et al. Overexpression of CD44 is associated with the occurrence and migration of non-small cell lung cancer. Mol Med Rep 2016; 14(4): 3159-67.
[52]
Anand V, Sharma A. CD44: A Multifaceted Molecule in Cancer Progression. J Cancer Prev Curr Res 2017; 8(3): 00279.
[53]
Senbanjo LT, Chellaiah MA. CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells. Front Cell Dev Biol 2017; 5: 18.
[54]
Dzwonek J, Wilczynski GM. CD44: molecular interactions, signaling and functions in the nervous system. Front Cell Neurosci 2015; 9: 175.
[55]
Yasuda M, Tanaka Y, Fujii K, Yasumoto K. CD44 stimulation down-regulates Fas expression and Fas-mediated apoptosis of lung cancer cells. Int Immunol 2001; 13(10): 1309-19.
[56]
Inamura K, Ninomiya H, Ishikawa Y, Matsubara O. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med 2010; 134(1): 66-72.
[57]
Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis 2010; 2(1): 48-51.
[58]
Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014; 2014: 852-48.
[59]
Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118(2): 257-62.
[61]
Lin Y, Zheng Y. Approaches of targeting Rho GTPases in cancer drug discovery. Expert Opin Drug Discov 2015; 10(9): 991-1010.
[62]
Kazanietz MG, Caloca MJ. The Rac GTPase in cancer: from old concepts to new paradigms. Cancer Res 2017; 77(20): 5445-51.
[63]
Parri M, Chiarugi P. Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal 2010; 8(1): 23.
[64]
Nayak RC, Chang KH, Vaitinadin NS, Cancelas JA. Rho GTPases control specific cytoskeleton-dependent functions of hematopoietic stem cells. Immunol Rev 2013; 256(1): 255-68.
[65]
Sun D, Xu D, Zhang B. Rac signaling in tumorigenesis and as target for anticancer drug development. Drug Resist Updat 2006; 9(6): 274-87.
[66]
Porter AP, Papaioannou A, Malliri A. Deregulation of Rho GTPases in cancer. Small GTPases 2016; 7(3): 123-38.
[68]
Ebi H, Costa C, Faber AC, et al. PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proc Natl Acad Sci USA 2013; 110(52): 21124-9.
[70]
Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 2010; 10(12): 842-57.
[71]
Blundell MP, Worth A, Bouma G, Thrasher AJ. The Wiskott-Aldrich syndrome: The actin cytoskeleton and immune cell function. Dis Markers 2010; 29(3-4): 157-75.
[72]
Ishihara D, Dovas A, Hernandez L, et al. Wiskott-Aldrich syndrome protein regulates leukocyte-dependent breast cancer metastasis. Cell Reports 2013; 4(3): 429-36.
[73]
Frugtniet B, Jiang WG, Martin TA. Role of the WASP and WAVE family proteins in breast cancer invasion and metastasis. Breast Cancer (Dove Med Press) 2015; 7: 99-109.
[74]
Frugtniet BA, Martin TA, Zhang L, Jiang WG. Neural Wiskott-Aldrich syndrome protein (nWASP) is implicated in human lung cancer invasion. BMC Cancer 2017; 17(1): 224.
[75]
Campellone KG, Webb NJ, Znameroski EA, Welch MD. WHAMM is an Arp2/3 complex activator that binds microtubules and functions in ER to Golgi transport. Cell 2008; 134(1): 148-61.
[76]
Kurisu S, Takenawa T. WASP and WAVE family proteins: friends or foes in cancer invasion? Cancer Sci 2010; 101(10): 2093-104.
[77]
Takenawa T, Suetsugu S. The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol 2007; 8(1): 37-48.
[78]
Sossey-Alaoui K. Surfing the big WAVE: Insights into the role of WAVE3 as a driving force in cancer progression and metastasis. Semin Cell Dev Biol 2013; 24(4): 287-97.
[79]
Joseph N, Biber G, Fried S, et al. A conformational change within the WAVE2 complex regulates its degradation following cellular activation. Sci Rep 2017; 7: 44863.
[80]
Sowalsky AG, Sager R, Schaefer RJ, et al. Loss of Wave1 gene defines a subtype of lethal prostate cancer. Oncotarget 2015; 6(14): 12383-91.
[81]
Padrick SB, Rosen MK. Physical mechanisms of signal integration by WASP family proteins. Annu Rev Biochem 2010; 79: 707-35.
[82]
Kumar R, Panwar B, Chauhan JS, Raghava GP. Analysis and prediction of cancerlectins using evolutionary and domain information. BMC Res Notes 2011; 4(1): 237.
[83]
Yang R, Zhang C, Zhang L, Gao R. A two-step feature selection method to predict cancerlectins by multiview features and synthetic minority oversampling technique. BioMed Res Int 2018; 2018: 9364182.
[84]
Lai H-Y, Chen XX, Chen W, Tang H, Lin H. Sequence-based predictive modeling to identify cancerlectins. Oncotarget 2017; 8(17): 28169-75.
[85]
Lin H, Liu WX, He J, Liu XH, Ding H, Chen W. Predicting cancerlectins by the optimal g-gap dipeptides. Sci Rep 2015; 5: 16964.
[86]
Zhang J, Ju Y, Lu H, Xuan P, Zou Q. Accurate identification of cancerlectins through hybrid machine learning technology. Int J Genomics 2016; 2016: 7604641.
[87]
Szöke T, Kayser K, Baumhakel JD, et al. Prognostic significance of endogenous adhesion/growth-regulatory lectins in lung cancer. Oncology 2005; 69(2): 167-74.
[88]
Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011; 378(9805): 1812-23.
[89]
Olsson E, Honeth G, Bendahl PO, et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 2011; 11(1): 418.
[90]
Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100(9): 672-9.
[91]
Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 2012; 136(2): 331-45.
[92]
Wang F, Weaver VM, Peterson OW, et al. Reciprocal interactions between Beta1-integrin and epidermal growth factor in three-dimensional basement membrane breast cultures: A different perspective in epithelial biology. Proc Natl Acad Sci USA 1998; 95(25): 14821-6.
[93]
Ali R, Wendt MK. The paradoxical functions of EGFR during breast cancer progression. 2017. 2 p. sigtrans201642
[94]
Bessette DC, Tilch E, Seidens T, et al. Using the MCF10A/ MCF10CA1a breast cancer progression cell line model to investigate the effect of active, mutant forms of EGFR in breast cancer development and treatment using gefitinib. PLoS One 2015; 10(5): e0125232.
[95]
Fedele M, Cerchia L, Chiappetta G. The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas. Cancers (Basel) 2017; 9(10): 134.
[96]
Lomakina ME, Lallemand F, Vacher S, et al. Arpin downregulation in breast cancer is associated with poor prognosis. Br J Cancer 2016; 114(5): 545-53.
[97]
Kulkarni S, Augoff K, Rivera L, et al. Increased expression levels of WAVE3 are associated with the progression and metastasis of triple negative breast cancer. PLoS One 2012; 7(8): e42895.
[98]
Salatino M, Rabinovich GA. Fine-tuning antitumor responses through the control of galectin–glycan interactions: an overview. Methods Mol Biol 2011; 677: 355-74.
[99]
Fry SA, Afrough B, Lomax-Browne HJ, Timms JF, Velentzis LS, Leathem AJ. Lectin microarray profiling of metastatic breast cancers. Glycobiology 2011; 21(8): 1060-70.
[101]
Sacks JD, Barbolina MV. Expression and function of CD44 in epithelial ovarian carcinoma. Biomolecules 2015; 5(4): 3051-66.
[102]
Djordjevic B, Stojanovic S, Conic I, et al. Current approach to epithelial ovarian cancer based on the concept of cancer stem cells. J BUON 2012; 17(4): 627-36.
[103]
Sosulski A, Horn H, Zhang L, et al. CD44 splice variant v8-10 as a marker of serous ovarian cancer prognosis. PLoS One 2016; 11(6): e0156595.
[104]
Ween MP, Oehler MK, Ricciardelli C. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci 2011; 12(2): 1009-29.
[105]
Zhang J, Chang B, Liu J. CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis. Hum Pathol 2013; 44(9): 1882-9.
[106]
Gao Y, Foster R, Yang X, et al. Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer. Oncotarget 2015; 6(11): 9313-26.
[107]
Wilken JA, Badri T, Cross S, et al. EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem 2012; 4(4): 447-69.
[108]
Teplinsky E, Muggia F. EGFR and HER2: is there a role in ovarian cancer? Transl Cancer Res 2015; 4(1): 107-17.
[109]
Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer 2011; 104(8): 1241-5.
[110]
Siwak DR, Carey M, Henne SSYBT, et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2010; 2010: 568938.
[111]
Reyes HD, Thiel KW, Carlson MJ, et al. Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers. Mol Diagn Ther 2014; 18(2): 137-51.
[112]
Bid HK, Roberts RD, Manchanda PK, Houghton PJ. RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis. Mol Cancer Ther 2013; 12(10): 1925-34.
[113]
Sanz-Moreno V. Tumour invasion: a new twist on Rac-driven mesenchymal migration. Curr Biol 2012; 22(11): R449-51.
[115]
Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, et al. Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer. Clin Cancer Res 2015; 21(9): 2127-37.
[116]
Chen B, Chou HT, Brautigam CA, et al. Rac1 GTPase activates the WAVE regulatory complex through two distinct binding sites. eLife 2017; 6: 6.
[117]
Zhang J, Tang L, Shen L, et al. High level of WAVE1 expression is associated with tumor aggressiveness and unfavorable prognosis of epithelial ovarian cancer. Gynecol Oncol 2012; 127(1): 223-30.
[118]
Yang MH, Zhao MY, He YL, et al. [Interaction of WAVE1 and
genes involved in multiple drug resistance in children with acute
myeloblastic leukemia]. Zhonghua Er Ke Za Zhi 2010; 48(3): 175-9.
[119]
Zhang J, Zhou S, Tang L, et al. WAVE1 gene silencing via RNA interference reduces ovarian cancer cell invasion, migration and proliferation. Gynecol Oncol 2013; 130(2): 354-61.
[120]
Kurisu S, Suetsugu S, Yamazaki D, Yamaguchi H, Takenawa T. Rac-WAVE2 signaling is involved in the invasive and metastatic phenotypes of murine melanoma cells. Oncogene 2005; 24(8): 1309-19.
[121]
Lu J, Wang SL, Wang YC, et al. High WAVE3 expression correlates with proliferation, migration and invasion in human ovarian cancer. Oncotarget 2017; 8(25): 41189-201.
[122]
Zhao R, Qin W, Qin R, et al. Lectin array and glycogene expression analyses of ovarian cancer cell line A2780 and its cisplatin-resistant derivate cell line A2780-cp. Clin Proteomics 2017; 14(1): 20.
[123]
Marley AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet 2016; 7(3): 105-14.
[124]
Zeilstra J, Joosten SP, Vermeulen L, et al. CD44 expression in intestinal epithelium and colorectal cancer is independent of p53 status. PLoS One 2013; 8(8): e72849.
[125]
Iseki Y, Shibutani M, Maeda K, Nagahara H, Ikeya T, Hirakawa K. Significance of E-cadherin and CD44 expression in patients with unresectable metastatic colorectal cancer. Oncol Lett 2017; 14(1): 1025-34.
[126]
Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16(1): 15-31.
[127]
Hutchinson RA, Adams RA, McArt DG, Salto-Tellez M, Jasani B, Hamilton PW. Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. J Transl Med 2015; 13(1): 217.
[128]
Jiang Z, Li C, Li F, Wang X. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis. PLoS One 2013; 8(2): e56205.
[129]
Marei H, Malliri A. Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms. Small GTPases 2017; 8(3): 139-63.
[130]
Zhou C, Licciulli S, Avila JL, et al. The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis. Oncogene 2013; 32(7): 903-9.
[131]
Matos P, Kotelevets L, Goncalves V, et al. Ibuprofen inhibits colitis-induced overexpression of tumor-related Rac1b. Neoplasia 2013; 15(1): 102-11.
[132]
Lane J, Martin T, Weeks HP, Jiang WG. Structure and role of WASP and WAVE in Rho GTPase signalling in cancer. Cancer Genomics Proteomics 2014; 11(3): 155-65.
[133]
Martin TA, Toms AM, Davies LM, Cheng S, Jiang WG. The clinical and biological implications of N-WASP expression in human colorectal cancer. Transl Gastrointest Cancer 2012; 1(1): 10-20.
[134]
Qiu Y, Patwa TH, Xu L, et al. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res 2008; 7(4): 1693-703.
[135]
Perez-Cornago A, Key TJ, Allen NE, et al. Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study. Br J Cancer 2017; 117(10): 1562-71.
[136]
Montanari M, Rossetti S, Cavaliere C, et al. Epithelial-mesenchymal transition in prostate cancer: an overview. Oncotarget 2017; 8(21): 35376-89.
[137]
Xu H, Tian Y, Yuan X, et al. The role of CD44 in epithelial-mesenchymal transition and cancer development. OncoTargets Ther 2015; 8: 3783-92.
[138]
Stivarou T, Patsavoudi E. Extracellular molecules involved in cancer cell invasion. Cancers (Basel) 2015; 7(1): 238-65.
[139]
Marín-Aguilera M, Codony-Servat J, Reig Ò, et al. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol Cancer Ther 2014; 13(5): 1270-84.
[140]
Deep G, Jain AK, Ramteke A, et al. SNAI1 is critical for the aggressiveness of prostate cancer cells with low E-cadherin. Mol Cancer 2014; 13(1): 37.
[141]
Yu D, Shin HS, Lee YS, Lee YC. miR-106b modulates cancer stem cell characteristics through TGF-β/Smad signaling in CD44-positive gastric cancer cells. Lab Invest 2014; 94(12): 1370-81.
[142]
Ju S-Y, Chiou S-H, Su Y. Maintenance of the stemness in CD44(+) HCT-15 and HCT-116 human colon cancer cells requires miR-203 suppression. Stem Cell Res (Amst) 2014; 12(1): 86-100.
[143]
Cho SH, Park YS, Kim HJ, et al. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol 2012; 41(1): 211-8.
[144]
Fernando J, Malfettone A, Cepeda EB, et al. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. Int J Cancer 2015; 136(4): E161-72.
[145]
Shang Z, Cai Q, Zhang M, et al. A switch from CD44+ cell to EMT cell drives the metastasis of prostate cancer. Oncotarget 2015; 6(2): 1202-16.
[146]
Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25(12): 1696-708.
[147]
Wang C-C, De Marzo AM, Lotan TL, Epstein JI. Overlap of CD44 expression between prostatic small cell carcinoma and acinar adenocarcinoma. Hum Pathol 2015; 46(4): 554-7.
[148]
Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002; 7(Suppl. 4): 31-9.
[149]
Day KC, Lorenzatti GH, Kozminsky M, et al. HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res 2017; 77(1): 74-85.
[150]
Cai CQ, Peng Y, Buckley MT, et al. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene 2008; 27(22): 3201-10.
[151]
Kharmate G, Hosseini-Beheshti E, Caradec J, Chin MY, Tomlinson Guns ES. Epidermal growth factor receptor in prostate cancer derived exosomes. PLoS One 2016; 11(5): e0154967.
[152]
DeHaan AM, Wolters NM, Keller ET, Ignatoski KM. EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. Prostate 2009; 69(5): 528-37.
[153]
Kato T, Kawai K, Egami Y, Kakehi Y, Araki N. Rac1-dependent lamellipodial motility in prostate cancer PC-3 cells revealed by optogenetic control of Rac1 activity. PLoS One 2014; 9(5): e97749.
[154]
Fernando HS, Sanders AJ, Kynaston HG, Jiang WG. WAVE3 is associated with invasiveness in prostate cancer cells. Urol Oncol 2010; 28(3): 320-7.
[155]
Teng Y, Ren MQ, Cheney R, Sharma S, Cowell JK. Inactivation of the WASF3 gene in prostate cancer cells leads to suppression of tumorigenicity and metastases. Br J Cancer 2010; 103(7): 1066-75.
[156]
Basu PS, Majhi R, Batabyal SK. Lectin and serum-PSA interaction as a screening test for prostate cancer. Clin Biochem 2003; 36(5): 373-6.
[157]
Li X-P, Zhang XW, Zheng LZ, Guo WJ. Expression of CD44 in pancreatic cancer and its significance. Int J Clin Exp Pathol 2015; 8(6): 6724-31.
[158]
Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11(4): 254-67.
[159]
Li Z, Chen K, Jiang P, Zhang X, Li X, Li Z. CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients. Diagn Pathol 2014; 9(1): 79.
[160]
Brown RL, Reinke LM, Damerow MS, et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011; 121(3): 1064-74.
[161]
Preca BT, Bajdak K, Mock K, et al. A self-enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells. Int J Cancer 2015; 137(11): 2566-77.
[162]
Bera A. VenkataSubbaRao K, Manoharan MS, Hill P, Freeman JW. A miRNA signature of chemoresistant mesenchymal phenotype identifies novel molecular targets associated with advanced pancreatic cancer. PLoS One 2014; 9(9): e106343.
[163]
Biddle A, Gammon L, Fazil B, Mackenzie IC. CD44 staining of cancer stem-like cells is influenced by down-regulation of CD44 variant isoforms and up-regulation of the standard CD44 isoform in the population of cells that have undergone epithelial-to-mesenchymal transition. PLoS One 2013; 8(2): e57314.
[164]
Zhao S, Chen C, Chang K, et al. CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy. Clin Cancer Res 2016; 22(22): 5592-604.
[165]
Li L, Hao X, Qin J, et al. Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice. Gastroenterology 2014; 146(4): 1108-18.
[166]
Jiang W, Zhang Y, Kane KT, et al. CD44 regulates pancreatic cancer invasion through MT1-MMP. Mol Cancer Res 2015; 13(1): 9-15.
[167]
Yang K, Tang Y, Habermehl GK, Iczkowski KA. Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity. BMC Cancer 2010; 10(1): 16.
[168]
Handra-Luca A, Hammel P, Sauvanet A, Lesty C, Ruszniewski P, Couvelard A. EGFR expression in pancreatic adenocarcinoma. Relationship to tumour morphology and cell adhesion proteins. J Clin Pathol 2014; 67(4): 295-300.
[169]
Luo G, Long J, Qiu L, Liu C, Xu J, Yu X. Role of epidermal growth factor receptor expression on patient survival in pancreatic cancer: a meta-analysis. Pancreatology 2011; 11(6): 595-600.
[170]
Oliveira-Cunha M, Newman WG, Siriwardena AK. Epidermal growth factor receptor in pancreatic cancer. Cancers (Basel) 2011; 3(2): 1513-26.
[172]
Yan Y, Hein AL, Etekpo A, et al. Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to γ-irradiation. Oncotarget 2014; 5(21): 10251-70.
[173]
Guo J-C, Li J, Zhao YP, et al. N-wasp in pancreatic ductal adenocarcinoma: associations with perineural invasion and poor prognosis. World J Surg 2014; 38(8): 2126-31.
[174]
Shimomura O, Oda T, Tateno H, et al. A Novel Therapeutic Strategy for Pancreatic Cancer: Targeting Cell Surface Glycan Using rBC2LC-N Lectin-Drug Conjugate (LDC). Mol Cancer Ther 2018; 17(1): 183-95.
[175]
Chen J, Zhou J, Lu J, Xiong H, Shi X, Gong L. Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis. BMC Cancer 2014; 14(1): 15.
[176]
Rajarajan A, Stokes A, Bloor BK, et al. CD44 expression in oro-pharyngeal carcinoma tissues and cell lines. PLoS One 2012; 7(1): e28776.
[177]
Athanassiou-Papaefthymiou M, Shkeir O, Kim D, et al. Evaluation of CD44 variant expression in oral, head and neck squamous cell carcinomas using a triple approach and its clinical significance. Int J Immunopathol Pharmacol 2014; 27(3): 337-49.
[178]
Emich H, Chapireau D, Hutchison I, Mackenzie I. The potential of CD44 as a diagnostic and prognostic tool in oral cancer. J Oral Pathol Med 2015; 44(6): 393-400.
[179]
Kimura I, Kitahara H, Ooi K, et al. Loss of epidermal growth factor receptor expression in oral squamous cell carcinoma is associated with invasiveness and epithelial-mesenchymal transition. Oncol Lett 2016; 11(1): 201-7.
[180]
Nantajit D, Lin D, Li JJ. The network of epithelial-mesenchymal transition: potential new targets for tumor resistance. J Cancer Res Clin Oncol 2015; 141(10): 1697-713.
[181]
Maiti GP, Mondal P, Mukherjee N, et al. Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes. PLoS One 2013; 8(5): e63440.
[182]
Chang K-Y, Tsai SY, Chen SH, et al. Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance. J Biomed Sci 2013; 20(1): 43.
[183]
Perez A, Neskey DM, Wen J, et al. CD44 interacts with EGFR and promotes head and neck squamous cell carcinoma initiation and progression. Oral Oncol 2013; 49(4): 306-13.
[184]
Chiu Y-W, Liou LY, Chen PT, et al. Tyrosine 397 phosphorylation is critical for FAK-promoted Rac1 activation and invasive properties in oral squamous cell carcinoma cells. Lab Invest 2016; 96(3): 296-306.
[185]
Yap LF, Jenei V, Robinson CM, et al. Upregulation of Eps8 in oral squamous cell carcinoma promotes cell migration and invasion through integrin-dependent Rac1 activation. Oncogene 2009; 28(27): 2524-34.
[186]
Mack NA, Whalley HJ, Castillo-Lluva S, Malliri A. The diverse roles of Rac signaling in tumorigenesis. Cell Cycle 2011; 10(10): 1571-81.
[187]
Liu S-Y, Yen CY, Yang SC, Chiang WF, Chang KW. Overexpression of Rac-1 small GTPase binding protein in oral squamous cell carcinoma. J Oral Maxillofac Surg 2004; 62(6): 702-7.
[188]
Baeten J, Suresh A, Johnson A, et al. Molecular imaging of oral premalignant and malignant lesions using fluorescently labeled lectins. Transl Oncol 2014; 7(2): 213-20.
[189]
Mansouri A, Foroughmand AM, Abbaszadegan MR, Memar B, Mahmoudian RA, Gholamin M. Expression analysis of CD44 isoforms S and V3, in patients with esophageal squamous cell carcinoma. Iran J Basic Med Sci 2015; 18(4): 380-4.
[190]
Shiozaki M, Ishiguro H, Kuwabara Y, et al. Expression of CD44v6 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma. Oncol Lett 2011; 2(3): 429-34.
[191]
Lin G, Sun XJ, Han QB, et al. Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma. Oncol Lett 2015; 10(2): 901-6.
[192]
Wang X, Niu H, Fan Q, et al. Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma. Oncotarget 2016; 7(17): 24744-51.
[193]
Yang Q, Luo GY, Li Y, Shan HB, Wang HY, Xu GL. Expression of Rac-1 related to tumor depth, lymph node metastasis and patient prognosis in esophageal squamous cell carcinoma. Med Oncol 2013; 30(4): 689.
[194]
Mechref Y, Hussein A, Bekesova S, et al. Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets. J Proteome Res 2009; 8(6): 2656-66.
[195]
Takeuchi K, Yamaguchi A, Urano T, Goi T, Nakagawara G, Shiku H. Expression of CD44 variant exons 8-10 in colorectal cancer and its relationship to metastasis. Jpn J Cancer Res 1995; 86(3): 292-7.
Related Journals
Current Drug Safety
Current Medicinal Chemistry
Current Neuropharmacology
Current Pharmaceutical Analysis
Current Topics in Medicinal Chemistry
Current Vascular Pharmacology
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
CNS & Neurological Disorders - Drug Targets
Related Books
New Findings from Natural Substances
Mitochondrial DNA and the Immuno-inflammatory Response: New Frontiers to Control Specific Microbial Diseases
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Frontiers in Clinical Drug Research – Anti Allergy Agents
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Postbiotics: Science, Technology and Applications
Frontiers in Inflammation
Article Metrics
32
4
1
1